All In Biotech

Drug Trial Radar · NCT07656376

Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation

Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 465 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

465

Planned (sponsor's estimate)

Start

Jun 6, 2027

Primary completion

Feb 7, 2029

Study completion May 8, 2029

Sponsor

Sponsor type
Industry
First posted
Jun 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation.The study consists of two stages I, Stage I :explores the combination dose and the second phase; Stage II :patients were randomized 1:1 to receive either the experimental regimen DN022150 plus AG or the control regimen AG alone.

Conditions

  • Pancreatic Cancer
  • Pancreatic Carcinoma

Interventions

  • DN022150+AG( Stage I )Drug

    28-day /cycle

  • DN022150+AG(Stage II)Drug

    28-day /cycle

  • placebo+AG(Stage II)Drug

    28-day /cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTTime frame: up to 2 years
  2. PFS as assessed by BICR per RECIST 1.1Time frame: up to 2 years
  3. OSTime frame: up to 2 years
  4. ORRTime frame: up to 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.